A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. We also have products to determine food quality and nutritional components. The majority of the test kits are consumables, single-use, culture, immunoassay and nucleic acid detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 880M | 895M | 924M | 822M | 527M | 468M |
| Net Income | -603M | -1.1B | -9.4M | -23M | 48M | 61M |
| EPS | $-2.78 | $-5.03 | $-0.04 | $-0.12 | $0.23 | $0.14 |
| Free Cash Flow | -18M | -46M | -76M | -25M | 44M | 54M |
| ROIC | -14.0% | -31.3% | 1.5% | 1.6% | 7.4% | 10.7% |
| Gross Margin | 46.0% | 47.1% | 50.2% | 49.4% | 46.1% | 45.9% |
| Debt/Equity | 0.76 | 0.43 | 0.28 | 0.28 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -627M | -1.1B | 59M | 38M | 59M | 74M |
| Operating Margin | -71.3% | -118.6% | 6.3% | 4.6% | 11.1% | 15.8% |
| ROE | -28.6% | -41.9% | -0.3% | -1.1% | 5.6% | 7.8% |
| Shares Outstanding | 218M | 217M | 236M | 191M | 215M | 427M |
NEOGEN CORP passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 47.7%. At current prices, the estimated annualized return to fair value is -37.9%.
NEOGEN CORP (NEOG) has a 5-year average return on invested capital (ROIC) of -2.0%. This is below average and may indicate limited pricing power.
NEOGEN CORP (NEOG) has a market capitalization of $2.1B. It is classified as a mid-cap stock.
NEOGEN CORP (NEOG) does not currently pay a regular dividend.
NEOGEN CORP (NEOG) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
NEOGEN CORP (NEOG) reported annual revenue of $895 million in its most recent fiscal year, based on SEC EDGAR filings.
NEOGEN CORP (NEOG) has a net profit margin of -122.1%. The company is currently unprofitable.
NEOGEN CORP (NEOG) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEOGEN CORP (NEOG) has a debt-to-equity ratio of 0.43. This indicates a conservatively financed balance sheet.
NEOGEN CORP (NEOG) reported earnings per share (EPS) of $-5.03 in its most recent fiscal year.
NEOGEN CORP (NEOG) has a return on equity (ROE) of -41.9%. A negative ROE may indicate losses or negative equity.
NEOGEN CORP (NEOG) has a 5-year average gross margin of 47.7%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for NEOGEN CORP (NEOG), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NEOGEN CORP (NEOG) has a book value per share of $9.54, based on its most recent annual SEC filing.
No recent press releases.